
FDA says Shifamed’s Myra Vision can begin glaucoma implant study
Myra Vision announced today that it received FDA investigational device exemption (IDE) approval for its Calibreye system
Myra Vision announced today that it received FDA investigational device exemption (IDE) approval for its Calibreye system
Renata Medical announced today that CMS granted a New Technology Add-on Payment (NTAP) for its Minima stent system.
Targeting cellular structures called nuclear speckles could be a completely new approach for treating proteinopathies—diseases driven by abnormal accumulation of misfolded proteins—such as Alzheimer’s, Parkinson’s and prion diseases.
A cancer drug could enhance how patients respond to chemotherapy even in treatment-resistant tumors. The drug works by disarming a key defense mechanism that tumors use to protect themselves from treatment.
Researchers at the German Center for Diabetes Research (DZD) in Potsdam and Tübingen have discovered small chemical modifications to genetic material (epigenetic changes) in the blood that indicate how well the brain responds to insulin.
Researchers at Boston University Chobanian & Avedisian School of Medicine have built an artificial intelligence (AI) tool that can accurately predict key signs of Alzheimer’s disease.
New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London in partnership with the Mayo Clinic and UNEEG medical, has found that an electronic device placed under the scalp is an effective and feasible means of accurately tracking epilepsy.
Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression.
TELFORD, Pa., Aug. 11, 2025 /PRNewswire/ — Today Dräger, an international leader in medical and safety technologies, announced that the company’s Atlan A350/A350 XL series of anesthesia workstations received Authority to Operate (ATO) certification under the Department of Defense’s (DoD) Risk Management Framework (RMF) eMASS #4060.
The method assesses growth rates of the tumour and detects gene patterns that can forecast outcomes of the patient.